IMAB
I-Mab
NASDAQ · Healthcare · Biotechnology · US
$2.88
−0.69%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 4.5M | (10.7M) | 88.0M |
| Cost of Revenue | — | — | — | 27.2M | 46.4M |
| Gross Profit | — | — | 4.5M | (248.8M) | 41.6M |
| Operating Expenses | |||||
| R&D Expense | 14.6M | 158.9M | 114.4M | 155.5M | 190.3M |
| SG&A Expense | 23.6M | 216.5M | 63.9M | 199.9M | 899.9M |
| General & Admin Expense | 23.6M | 216.5M | 63.9M | 815.8M | 899.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 337.4M | (247.00) | 1.0B |
| Total Operating Expenses | 38.2M | 375.4M | 515.6M | 355.4M | 2.1B |
| Cost and Expenses | 38.2M | 375.4M | 515.6M | 355.4M | 2.2B |
| Operating Income (EBIT) | (38.2M) | (375.4M) | (511.2M) | (366.1M) | (2.1B) |
| Non-Operating | |||||
| Interest Income | 8.3M | 54.6M | 7.3M | 5.0M | 21.3M |
| Interest Expense | — | — | 101.9K | — | — |
| Net Interest Income | 8.3M | 54.6M | 7.2M | 5.0M | 21.3M |
| Other Non-Op Income/Expense | (1.8M) | 12.6M | (954.5M) | (607.1M) | (260.7M) |
| Non-Operating Income (excl Interest) | (1.3M) | — | (163.5M) | — | — |
| EBT (Pre-Tax Income) | (40.0M) | (362.7M) | (1.5B) | (973.2M) | (2.3B) |
| Income Tax Expense | — | — | (1.3B) | 697.0K | (494.8K) |
| Bottom Line | |||||
| Net Income | (38.2M) | (162.3M) | (1.5B) | (2.5B) | (2.3B) |
| Earnings from Cont. Ops | (40.0M) | (362.7M) | (206.8M) | (2.5B) | (2.3B) |
| Earnings from Discont. Ops | 1.8M | 200.5M | — | — | — |
| Bottom Line Net Income | (38.2M) | (362.7M) | (1.5B) | (2.5B) | (2.3B) |
| Per Share | |||||
| Basic EPS | ($0.71) | ($4.46) | ($17.62) | ($30.38) | ($30.70) |
| Diluted EPS | ($0.71) | ($4.46) | ($17.62) | ($30.38) | ($30.68) |
| Revenue Per Share | $0.00 | $0.00 | $0.05 | ($0.13) | $1.16 |
| Shares | |||||
| Basic Shares Outstanding | 81.7M | 81.2M | 83.2M | 82.5M | 75.9M |
| Diluted Shares Outstanding | 81.7M | 81.2M | 83.2M | 82.5M | 76.0M |
| Profitability Metrics | |||||
| EBITDA | (30.9M) | (373.5M) | (344.3M) | (51.2M) | (2.1B) |
| D&A | 6.0M | 1.9M | 3.4M | 1.4M | 13.8M |
| EBIT | (36.9M) | (375.4M) | (347.6M) | (52.6M) | (2.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2025